Given the apparent superiority of EDP-323 and the lack of attractive partnership offers for Zeli, I don't get it why they didn't do a 323 phase 2b in the South hemisphere and directly proceed with a Phase 3 on 323 in the fall instead of pushing both. Trying to push both RSV drugs doesn't look to me like the best strategy here.
Market Data 
Markets 
AI
